This is the authors' abstract. We don't add key points for this paper.
These findings suggest that in adults with T2D, SGLT2i use may lower the risk of nephrolithiasis compared with GLP-1RAs or DPP4is and could help to inform decision-making when prescribing glucose-lowering agents for patients who may be at risk for developing nephrolithiasis.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Paik et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: